

Monthly review

During August, the Italian equity market continued to trade within a broadly range-bound pattern, influenced not only by developments in the conflict between Iran and the United States, but also by inflation data, which will be pivotal in shaping central banks' forthcoming policy decisions. The reporting season also drew to a close, delivering overall encouraging results, particularly within the banking and insurance sectors. The weakest area remained the automotive industry, where Stellantis continues to face pressure from the growing competitiveness of Chinese manufacturers. AI-related stocks experienced a marked increase in volatility, reflecting fluctuations across the broader technology sector. Against this backdrop, utilities corrected, weighed down by higher interest rates, while oil stocks also underperformed. By contrast, financials and banks outperformed, with the ongoing consolidation process continuing to dominate the sector narrative. Across the mid- and small-cap universe, corporate results were generally positive as well. From a sector allocation perspective, we maintained our underweight positions in utilities and oil-related stocks, while continuing to favour financials. Among our preferred holdings are Montepaschi and Unipol. During the month, we added to Sol and Fiera Milano, while exiting our positions in Iren, Acea and Ariston. Our most significant holdings within the small-cap segment remain Sol, Danieli risp, Mondadori and Philogen.

Key fund information

Assogestioni category	Azionario Italia
Inception date	05/04/1990
Nav (Euro)	76.380
AUM (in Euro)	143,394,286
Benchmark	50% FTSE Mib TR (NET) 50% FTSE Italia Mid Cap TR (NET)

Past performance is not indicative of current or future results.

Performance	Fund	Benchmark
YTD	9.05%	13.50%
Last week	0.50%	0.50%
Last month	0.69%	1.01%
Last 3 months	2.81%	2.88%
1 year	15.15%	20.08%
3 years (*)	21.68%	21.34%
5 years (*)	13.30%	13.01%
Since inception (*)	7.68%	-

(*) Compound annual return

Risk statistics

Standard deviation	16.05%	Sharpe ratio	1.12
Standard deviation bench	16.27%	Information ratio	-0.5
VaR	-26.49%	Beta	0.98
Tracking error volatility	2.25%	Correlation	0.99

Asset class

Shares	98.6%
Liquidity	1.4%
Bonds	-
Total	100.00%


Currency exposure

	Gross exp.	Coverage	Net exp.
Euro	100.0%	-	100.0%
Dollar	0.0%	-	0.0%
Europe ex Euro	0.0%	-	0.0%
Total	100.0%	-	100.0%

Equity portfolio structure


	Shares	Deriv	Total
Italy	91.8%	-	91.8%
Europe ex Italy	6.8%	-	6.8%
America	-	-	-
Total	98.6%	-	98.6%

Performance over last year






Composition by sector



Main securities in the portfolio



Fund technicals

Management Company	Ersel Gestion Internationale SA
Investment Manager	Ersel Asset Management Sgr SpA
Custodian bank	Caceis Bank Luxembourg SA
Independent auditors	Ernst & Young S.A.
Offices of Ersel Group	Piazza Solferino, 11 - 10121 Torino +39 01155201 35 Boulevard Joseph II, L-1840 Luxembourg
Base currency	Euro
ISIN code	LU1011692438
Bloomberg code	GLBPMIB LX
Frequency of NAV calculations	Giornaliera
NAV published on:	Sito Ersel

Investment objective

The fund predominantly invests in equity instruments listed in Italy or in shares of Italian issuers denominated in both Euro and foreign currency. Investments are made in small, medium and large capitalisation companies with the goal of obtaining adequate diversification in all economic sectors. The fund's main objective is appreciation of the value of capital over a long-term time horizon (indicatively over 7 years) with a high risk level. The investment philosophy is based on the centrality of fundamental analysis both by sector and individual company. Decisions are therefore made following research activity based on income prospects, valuation levels, cash flow analysis and risk control.

Conditions

Minimum investment	2.500 euro
Subsequent investments	0
Subscription fees	0
Redemption fees	0
Management fees	1,75% on an annual basis
Performance fees	15% of the difference recorded in the reference period between the percentage change in the unit value in the calendar year and the percentage change in the benchmark in the same period.

Risk level

1	2	3	4	5	6	7
---	---	---	---	---	---	---

The synthetic risk indicator assumes that the product is held for 5 years and is an indicative indication of the level of risk of this product compared to other products.

General notices

Marketing Communication. This document is intended for information/marketing purposes only and does not replace the prospectus or other legal documents on financial products that may be referred to herein. If necessary, please consult the UCITS prospectus/disclosure document and the Key Investor Document (KID) before making a final investment decision, which can only be made after assessing the suitability of the service or financial instrument with respect to the profile identified with the MiFID questionnaire. Only the most recent version of the fund's prospectus, regulations, Key Investor Document, annual and semi-annual reports may be used as a basis for investment decisions. This document constitutes neither an offer nor a solicitation to buy, subscribe or sell financial products or instruments or a solicitation to make investments. Ersel has carefully reviewed all information presented in this document and made efforts to ensure that the content of this document is based on information and data obtained from reliable sources, but does not guarantee its accuracy or completeness and does not assume any liability. Ersel assumes no responsibility for the information, projections or opinions contained herein and shall not be liable for any use that third parties may make of such information or for any losses or damages that may occur as a result of such use. This document may refer to past investment performance: past performance is not indicative of current or future performance. The indications and data on the financial instruments, as provided by the Company, do not necessarily constitute an indicator of the future investment or disinvestment prospects. Any reproduction and/or distribution of this document that is not expressly authorised is prohibited.